A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M.
Invest New Drugs. 2007 Jun;25(3):247-52. Epub 2006 Oct 5.PMID: 17021960 [PubMed - indexed for MEDLINE]Related articles